)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Heron Therapeutics
Heron Therapeutics (HRTX) investor relations material
Heron Therapeutics Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary9 Nov, 2026
Executive summary
Q3 2026 net revenue was $35.250M, down 7.8% YoY; Acute Care growth was offset by lower Oncology revenue.
A definitive agreement was signed Nov. 8 for CorMedix to acquire substantially all operating assets; closing is expected in Q1 2027, subject to stockholder approval and other conditions.
Financial highlights
Q3 gross profit was $26.292M vs. $26.299M YoY; 9M gross profit was $76.5M vs. $84.1M.
Q3 net loss was $5.006M vs. $17.495M; 9M net loss was $18.6M vs. $17.2M. Q3 2025 included an $11.339M debt-extinguishment loss.
Adjusted EBITDA was $3.700M in Q3 vs. $1.542M; 9M Adjusted EBITDA was $6.224M vs. $9.530M.
9M net product sales were $107.6M vs. $114.3M.
Outlook and guidance
2026 full-year financial guidance was withdrawn in August; no guidance is currently being provided.
Available cash and short-term investments were expected to cover anticipated operating needs for at least one year from issuance, but covenant compliance may require additional funding or a waiver.
Following the asset-sale closing, plans are to assess strategic transactions and investments; future business choices and revenue prospects remain uncertain.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Heron Therapeutics
- CorMedix deal offers $222.6M upfront plus contingent value, pending approval.HRTX
Proxy filing - Asset sale preserves public status and leaves upside in royalties and ZYNRELEF milestones.HRTXProxy filing
- Q2 2026 net revenue was $37.7M, with guidance withdrawn amid patent and generic uncertainty.HRTXQ2 2026
- All director nominees and proposals were approved, with no questions from stockholders.HRTXAGM 2026
- Q1 2026 net sales $34.7M; Acute Care up, Oncology down; guidance reaffirmed.HRTXQ1 2026
- Shareholders will vote on directors, compensation, equity plans, and tax benefit protections.HRTXProxy filing
- Key votes include director elections, plan amendments, and auditor ratification for 2026.HRTXProxy filing
- Q2 2024 sales rose to $36M, margin improved, and ZYNRELEF set for growth with VAN and NOPAIN Act.HRTXQ2 2024
- Achieved full-year profitability and 14% revenue growth, led by ZYNRELEF and APONVIE momentum.HRTXQ4 2024
Next Heron Therapeutics earnings date
Q4 20261 Mar, 2027
Heron Therapeutics
Next Heron Therapeutics earnings date
Q4 20261 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Heron Therapeutics Inc. is a biotechnology company focused on developing and commercializing therapies to address unmet medical needs in acute care and oncology. The company specializes in creating treatments for pain management and chemotherapy-induced side effects, such as nausea and vomiting. Heron Therapeutics utilizes its proprietary technology platforms to develop extended-release therapies that aim to improve patient comfort and treatment outcomes. The company is headquartered in San Diego, California, and its shares are listed on the NASDAQ.